Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increasing adoption of donation after circulatory death in high-risk heart transplant recipients: Insights into current practices in the United States.

JTCVS open·2026
Same author

Allosensitization From Blood Transfusion in Pediatric Solid Organ Transplant Candidates: Impact of Irradiation.

Pediatric transplantation·2026
Same author

Low Burden of Arrhythmia in Pediatric Patients and Patients With Congenital Heart Disease Participating in Cardiac Rehabilitation.

Journal of the American Heart Association·2025
Same author

The Relationship of Handgrip Strength to Body Composition and Cardiopulmonary Fitness in Children and Young Adults.

Journal of pediatrics. Clinical practice·2025
Same author

Bioelectrical Impedance Analysis and How it Correlates to Intracardiac Hemodynamics in Patients with Congenital Heart Disease.

Pediatric cardiology·2025
Same author

Malnutrition-related cardiomyopathy in a pediatric patient with autism spectrum disorder.

JPGN reports·2025

Related Experiment Video

Updated: May 23, 2026

Murine Heterotopic Heart Transplant Technique
10:27

Murine Heterotopic Heart Transplant Technique

Published on: July 8, 2014

Cardiac antibody-mediated rejection.

Clifford Chin1

  • 1The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA.

Pediatric Transplantation
|April 17, 2012
PubMed
Summary
This summary is machine-generated.

Pediatric heart transplant survival is limited by pre-existing antibodies against HLA, impacting outcomes. This review focuses on B cells, HLA antibodies, antibody-mediated rejection (AMR), and interventions to improve survival.

Related Experiment Videos

Last Updated: May 23, 2026

Murine Heterotopic Heart Transplant Technique
10:27

Murine Heterotopic Heart Transplant Technique

Published on: July 8, 2014

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pediatric Cardiology

Background:

  • Short- and long-term survival after pediatric heart transplantation is often limited by various factors.
  • Historically, research focused on T-cell responses and acute cellular rejection.
  • Pretransplant antibodies against Human Leukocyte Antigen (HLA) are linked to longer wait times and worse post-transplant outcomes.

Purpose of the Study:

  • To review the negative effects of B cells and HLA antibodies in pediatric heart transplantation.
  • To discuss Antibody-Mediated Rejection (AMR) and its impact on transplant outcomes.
  • To explore potential interventions for mitigating antibody-related complications.

Main Methods:

  • Literature review of studies on pediatric heart transplantation.
  • Analysis of the role of B cells and HLA antibodies.
  • Examination of current and emerging therapeutic strategies.

Main Results:

  • Pretransplant HLA antibodies are associated with increased donor wait times and poorer graft survival.
  • Antibody-Mediated Rejection (AMR) is a significant cause of graft dysfunction and failure.
  • Various therapies exist to mitigate circulating antibodies, including plasmapheresis and immunoadsorption.

Conclusions:

  • B cells and HLA antibodies play a critical role in limiting pediatric heart transplant success.
  • Effective management of antibody-related complications, including AMR, is crucial for improving long-term survival.
  • Further research into targeted therapies is needed to optimize outcomes in this vulnerable population.